A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross-Protection Activity against Multiple SARS-CoV-2 Sublineages

被引：21

作者：

Zhang, Xiantao ^{[1
]}

Wu, Shijian ^{[1
]}

Liu, Jie ^{[1
]}

Chen, Ran ^{[1
]}

Zhang, Yongli ^{[1
]}

Lin, Yingtong ^{[1
]}

Xi, Zhihui ^{[1
]}

Deng, Jieyi ^{[1
]}

Pu, Zeyu ^{[1
]}

Liang, Chaofeng ^{[1
]}

Feng, Jinzhu ^{[1
]}

Li, Rong ^{[1
]}

Lin, Keming ^{[1
]}

Zhou, Mo ^{[1
]}

Liu, Yingying ^{[1
]}

Zhang, Xu ^{[1
]}

Liu, Bingfeng ^{[1
]}

Zhang, Yiwen ^{[1
]}

He, Xin ^{[1
]}

Zhang, Hui ^{[1
,2
]}

机构：

[1] Sun Yat Sen Univ, Dept Pathogen Biol & Biosecur, Zhongshan Sch Med, Inst Human Virol,Key Lab Trop Dis Control,Minist E, Guangzhou 510080, Peoples R China

[2] Guangzhou Natl Lab, Guangzhou 510320, Peoples R China

来源：

ADVANCED SCIENCE | 2023年 / 10卷 / 27期

基金：

中国国家自然科学基金;

关键词：

broad neutralizing antibody; mosaic nanoparticle vaccine; mucosal immune responses; SARS-CoV-2; universal vaccines; INFECTION;

D O I：

10.1002/advs.202301034

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Because of the rapid mutation and high airborne transmission of SARS-CoV-2, a universal vaccine preventing the infection in the upper respiratory tract is particularly urgent. Here, a mosaic receptor-binding domain (RBD) nanoparticle (NP) vaccine is developed, which induces more RBD-targeted type IV neutralizing antibodies (NAbs) and exhibits broad cross-protective activity against multiple SARS-CoV-2 sublineages including the newly-emerged BF.7, BQ.1, XBB. As several T-cell-reactive epitopes, which are highly conserved in sarbecoviruses, are displayed on the NP surface, it also provokes potent and cross-reactive cellular immune responses in the respiratory tissue. Through intranasal delivery, it elicits robust mucosal immune responses and full protection without any adjuvants. Therefore, this intranasal mosaic NP vaccine can be further developed as a pan-sarbecovirus vaccine to block the viral entrance from the upper respiratory tract.

引用

页数：12